E-mail Address
Forgot your password? Click here to reset it

Request an Account


February 10, 2014
Melinta Therapeutics Raises $70 Million to Support Delafloxacin NDA and Selection of Multi-Drug Resistant Gram-Negative Candidates from RX-04 Platform

October 7, 2013
Melinta Therapeutics Announces Strategic Realignment and New Corporate Identity Based on Strong Scientific Foundation of Rib-X Pharmaceuticals

June 10, 2013
Pearl Therapeutics to be Acquired by AstraZeneca for up to $1.15 Billion

May 14, 2013
Rib-X Pharmaceuticals Initiates Delafloxacin Global Phase 3 Clinical Trial in Patients with Acute Bacterial Skin and Skin Structure Infections

May 13, 2013
Pearl Therapeutics Initiates PT003 Phase 3 Program for the Treatment of Individuals with Moderate-to-Severe COPD

November 29, 2012
Rib-X Pharmaceuticals Closes First Tranche in $67.5 Million Financing

November 13, 2012
Pearl Therapeutics Raises $65 Million Series D to Start PT003 Phase 3